APUS

Apimeds Pharmaceuticals US
APUS

7 hedge funds and large institutions have $649K invested in Apimeds Pharmaceuticals US in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 4 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less capital invested

Capital invested by funds: $ → $

less funds holding

Funds holding: →

less first-time investments, than exits

New positions opened: | Existing positions closed:

Holders
7
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$58K
2
+$51.2K
3
+$8.82K
4
UBS Group
UBS Group
Switzerland
+$1.24K
5
Bank of America
Bank of America
North Carolina
+$23

Top Sellers

1
-$49.6K
2
-$33.3K
3
-$24K
4
JP Morgan Chase
JP Morgan Chase
New York
-$14
Name Holding Trade Value Shares
Change 		Change in
Stake
HTHT
1
Hemenway Trust Hemenway Trust
New Hampshire
$449K
Vanguard Group
2
Vanguard Group
Pennsylvania
$96.7K
Geode Capital Management
3
Geode Capital Management
Massachusetts
$57.2K
Jane Street
4
Jane Street
New York
$44.6K
UBS Group
5
UBS Group
Switzerland
$954
Bank of America
6
Bank of America
North Carolina
$66
TRCT
7
Tower Research Capital (TRC)
New York
$16
Renaissance Technologies
8
Renaissance Technologies
New York
–
XT
9
XTX Topco
Cayman Islands
–
HF
10
HRT Financial
New York
–
JP Morgan Chase
11
JP Morgan Chase
New York
–